<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36011997</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1660-4601</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>16</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>International journal of environmental research and public health</Title><ISOAbbreviation>Int J Environ Res Public Health</ISOAbbreviation></Journal><ArticleTitle>Lowered Quality of Life in Long COVID Is Predicted by Affective Symptoms, Chronic Fatigue Syndrome, Inflammation and Neuroimmunotoxic Pathways.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10362</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijerph191610362</ELocationID><Abstract><AbstractText>The physio-affective phenome of Long COVID-19 is predicted by (a) immune-inflammatory biomarkers of the acute infectious phase, including peak body temperature (PBT) and oxygen saturation (SpO2), and (b) the subsequent activation of immune and oxidative stress pathways during Long COVID. The purpose of this study was to delineate the effects of PBT and SpO2 during acute infection, as well as the increased neurotoxicity on the physical, psychological, social and environmental domains of health-related quality of life (HR-QoL) in people with Long COVID. We recruited 86 participants with Long COVID and 39 normal controls, assessed the WHO-QoL-BREF (World Health Organization Quality of Life Instrument-Abridged Version, Geneva, Switzerland) and the physio-affective phenome of Long COVID (comprising depression, anxiety and fibromyalgia-fatigue rating scales) and measured PBT and SpO2 during acute infection, and neurotoxicity (NT, comprising serum interleukin (IL)-1&#x3b2;, IL-18 and caspase-1, advanced oxidation protein products and myeloperoxidase, calcium and insulin resistance) in Long COVID. We found that 70.3% of the variance in HR-QoL was explained by the regression on the physio-affective phenome, lowered calcium and increased NT, whilst 61.5% of the variance in the physio-affective phenome was explained by calcium, NT, increased PBT, lowered SpO2, female sex and vaccination with AstraZeneca and Pfizer. The effects of PBT and SpO2 on lowered HR-QoL were mediated by increased NT and lowered calcium yielding increased severity of the physio-affective phenome which largely affects HR-QoL. In conclusion, lowered HR-Qol in Long COVID is largely predicted by the severity of neuro-immune and neuro-oxidative pathways during acute and Long COVID.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maes</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute, Medical University Plovdiv, 4002 Plovdiv, Bulgaria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Barwon Health, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong 3217, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Rubaye</LastName><ForeName>Haneen Tahseen</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>College of Medical laboratory Techniques, Imam Ja'afar Al-Sadiq University, Najaf 54001, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almulla</LastName><ForeName>Abbas F</ForeName><Initials>AF</Initials><Identifier Source="ORCID">0000-0002-7667-6731</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf 54001, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Hadrawi</LastName><ForeName>Dhurgham Shihab</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Al-Najaf Center for Cardiac Surgery and Transcatheter Therapy, Najaf 54001, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stoyanova</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute, Medical University Plovdiv, 4002 Plovdiv, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kubera</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4401-5055</Identifier><AffiliationInfo><Affiliation>Laboratory of Immunoendocrinology, Department of Experimental Neuroendocrinology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna St., 31-343 Krakow, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Hakeim</LastName><ForeName>Hussein Kadhem</ForeName><Initials>HK</Initials><Identifier Source="ORCID">0000-0001-6143-5196</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, College of Science, University of Kufa, Kufa 54002, Iraq.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Environ Res Public Health</MedlineTA><NlmUniqueID>101238455</NlmUniqueID><ISSNLinking>1660-4601</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="Y">Fatigue Syndrome, Chronic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">myalgic encephalomyelitis/chronic fatigue syndrome</Keyword><Keyword MajorTopicYN="N">neuro-immune</Keyword><Keyword MajorTopicYN="N">psychiatry</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>1</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36011997</ArticleId><ArticleId IdType="pmc">PMC9408685</ArticleId><ArticleId IdType="doi">10.3390/ijerph191610362</ArticleId><ArticleId IdType="pii">ijerph191610362</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bastug A., Aslaner H., Aybar Bilir Y., Kemirtlek N., Gursoy F.M., Bastug S., Bodur H. Multiple system inflammatory syndrome associated with SARS-CoV-2 infection in an adult and an adolescent. Rheumatol. Int. 2021;41:993&#x2013;1008. doi: 10.1007/s00296-021-04843-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-04843-1</ArticleId><ArticleId IdType="pmc">PMC7978449</ArticleId><ArticleId IdType="pubmed">33742229</ArticleId></ArticleIdList></Reference><Reference><Citation>Vora S.M., Lieberman J., Wu H. Inflammasome activation at the crux of severe COVID-19. Nat. Rev. Immunol. 2021;21:694&#x2013;703. doi: 10.1038/s41577-021-00588-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00588-x</ArticleId><ArticleId IdType="pmc">PMC8351223</ArticleId><ArticleId IdType="pubmed">34373622</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus 6 October 2021. WHO; Geneva, Switzerland: 2021.</Citation></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., Liu M., Zhou X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., Villapol S. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci. Rep. 2021;11:16144. doi: 10.1038/s41598-021-95565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Badenoch J.B., Rengasamy E.R., Watson C., Jansen K., Chakraborty S., Sundaram R.D., Hafeez D., Burchill E., Saini A., Thomas L., et al. Persistent neuropsychiatric symptoms after COVID-19: A systematic review and meta-analysis. Brain Commun. 2021;4:fcab297. doi: 10.1093/braincomms/fcab297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab297</ArticleId><ArticleId IdType="pmc">PMC8833580</ArticleId><ArticleId IdType="pubmed">35169700</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hakeim H.K., Al-Rubaye H.T., Almulla A.F., Al-Hadrawi D.S., Maes M. Chronic fatigue, depression and anxiety symptoms in Long COVID are strongly predicted by neuroimmune and neuro-oxidative pathways which are caused by the inflammation during acute infection. medRxiv. 2022 doi: 10.1101/2022.06.29.22277056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.29.22277056</ArticleId><ArticleId IdType="pmc">PMC9865328</ArticleId><ArticleId IdType="pubmed">36675440</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hakeim H.K., Al-Rubabaye H.K., Al-Hadrawi D.S., Almulla A.F., Maes M. Long-COVID post-viral chronic fatigue syndrome and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: A proof of concept and mechanism study. medRxiv. 2022 doi: 10.1101/2022.04.25.22274251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.04.25.22274251</ArticleId><ArticleId IdType="pmc">PMC9589528</ArticleId><ArticleId IdType="pubmed">36280755</ArticleId></ArticleIdList></Reference><Reference><Citation>Renaud-Charest O., Lui L.M.W., Eskander S., Ceban F., Ho R., Di Vincenzo J.D., Rosenblat J.D., Lee Y., Subramaniapillai M., McIntyre R.S. Onset and frequency of depression in post-COVID-19 syndrome: A systematic review. J. Psychiatr. Res. 2021;144:129&#x2013;137. doi: 10.1016/j.jpsychires.2021.09.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2021.09.054</ArticleId><ArticleId IdType="pmc">PMC8482840</ArticleId><ArticleId IdType="pubmed">34619491</ArticleId></ArticleIdList></Reference><Reference><Citation>Titze-de-Almeida R., da Cunha T.R., Dos Santos Silva L.D., Ferreira C.S., Silva C.P., Ribeiro A.P., de Castro Moreira Santos J&#xfa;nior A., de Paula Brand&#xe3;o P.R., Silva A.P.B., da Rocha M.C.O., et al. Persistent, new-onset symptoms and mental health complaints in Long COVID in a Brazilian cohort of non-hospitalized patients. BMC. Infect. Dis. 2022;22:133. doi: 10.1186/s12879-022-07065-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07065-3</ArticleId><ArticleId IdType="pmc">PMC8821794</ArticleId><ArticleId IdType="pubmed">35135496</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandler C.X., Wyller V.B.B., Moss-Morris R., Buchwald D., Crawley E., Hautvast J., Katz B.Z., Knoop H., Little P., Taylor R., et al. Long COVID and Post-infective Fatigue Syndrome: A Review. Open Forum Infect. Dis. 2021;8:ofab440. doi: 10.1093/ofid/ofab440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab440</ArticleId><ArticleId IdType="pmc">PMC8496765</ArticleId><ArticleId IdType="pubmed">34631916</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Jassas H.K., Al-Hakeim H.K., Maes M. Intersections between pneumonia, lowered oxygen saturation percentage and immune activation mediate depression, anxiety, and chronic fatigue syndrome-like symptoms due to COVID-19: A nomothetic network approach. J. Affect. Disord. 2022;297:233&#x2013;245. doi: 10.1016/j.jad.2021.10.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2021.10.039</ArticleId><ArticleId IdType="pmc">PMC8541833</ArticleId><ArticleId IdType="pubmed">34699853</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hadrawi D.S., Al-Rubaye H.T., Almulla A.F., Al-Hakeim H.K., Maes M. Lowered oxygen saturation and increased body temperature in acute COVID-19 largely predict chronic fatigue syndrome and affective symptoms due to LONG COVID: A precision nomothetic approach. medRxiv. 2022 doi: 10.1101/2022.04.10.22273660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.04.10.22273660</ArticleId><ArticleId IdType="pubmed">36134517</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehr A.R., Perlman S. Coronaviruses: An overview of their replication and pathogenesis. Methods Mol. Biol. 2015;1282:1&#x2013;23. doi: 10.1007/978-1-4939-2438-7_1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-2438-7_1</ArticleId><ArticleId IdType="pmc">PMC4369385</ArticleId><ArticleId IdType="pubmed">25720466</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#x2019;Kovski P., Kratzel A., Steiner S., Stalder H., Thiel V. Coronavirus biology and replication: Implications for SARS-CoV-2. Nat. Rev. Microbiol. 2021;19:155&#x2013;170. doi: 10.1038/s41579-020-00468-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00468-6</ArticleId><ArticleId IdType="pmc">PMC7592455</ArticleId><ArticleId IdType="pubmed">33116300</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang H.F., Chan L.W.C., Cho W.C.S., Yu A.C.S., Yim A.K.Y., Chan A.K.C., Ng L.P.W., Wong Y.K.E., Pei X.M., Li M.J.W., et al. An update on COVID-19 pandemic: The epidemiology, pathogenesis, prevention and treatment strategies. Expert Rev. Anti Infect. Ther. 2021;19:877&#x2013;888. doi: 10.1080/14787210.2021.1863146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2021.1863146</ArticleId><ArticleId IdType="pubmed">33306423</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324:782&#x2013;793. doi: 10.1001/jama.2020.12839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12839</ArticleId><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagulkoo P., Plaimas K., Suratanee A., Colado Sim&#xe3;o A.N., Vissoci Reiche E.M., Maes M. Immunopathogenesis and immunogenetic variants in COVID-19. Curr. Pharm. Des. 2022 doi: 10.2174/1381612828666220519150821.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612828666220519150821</ArticleId><ArticleId IdType="pubmed">35598232</ArticleId></ArticleIdList></Reference><Reference><Citation>Yalcinkaya M., Liu W., Islam M.N., Kotini A.G., Gusarova G.A., Fidler T.P., Papapetrou E.P., Bhattacharya J., Wang N., Tall A.R. Modulation of the NLRP3 inflammasome by SARS-CoV-2 Envelope protein. Sci. Rep. 2021;11:24432. doi: 10.1038/s41598-021-04133-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-04133-7</ArticleId><ArticleId IdType="pmc">PMC8709866</ArticleId><ArticleId IdType="pubmed">34952919</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Tedesco Junior W.L.D., Lozovoy M.A.B., Mori M.T.E., Danelli T., Almeida E.R.D., Tejo A.M., Tano Z.N., Reiche E.M.V., Sim&#xe3;o A.N.C. In COVID-19, NLRP3 inflammasome genetic variants are associated with critical disease and these effects are partly mediated by the sickness symptom complex: A nomothetic network approach. Mol. Psychiatry. 2022;27:1945&#x2013;1955. doi: 10.1038/s41380-021-01431-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01431-4</ArticleId><ArticleId IdType="pmc">PMC8752583</ArticleId><ArticleId IdType="pubmed">35022530</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N., Di B., Xu L.-L. The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies. Cytokine Growth Factor Rev. 2021;61:2&#x2013;15. doi: 10.1016/j.cytogfr.2021.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2021.06.002</ArticleId><ArticleId IdType="pmc">PMC8233448</ArticleId><ArticleId IdType="pubmed">34183243</ArticleId></ArticleIdList></Reference><Reference><Citation>Tharakan S., Nomoto K., Miyashita S., Ishikawa K. Body temperature correlates with mortality in COVID-19 patients. Crit Care. 2020;24:298. doi: 10.1186/s13054-020-03045-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03045-8</ArticleId><ArticleId IdType="pmc">PMC7274509</ArticleId><ArticleId IdType="pubmed">32503659</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M.H., Stoyanov D. False dogmas in mood disorders research: Towards a nomothetic network approach. World J. Psychiatry. 2022;12:651&#x2013;667. doi: 10.5498/wjp.v12.i5.651.</Citation><ArticleIdList><ArticleId IdType="doi">10.5498/wjp.v12.i5.651</ArticleId><ArticleId IdType="pmc">PMC9150032</ArticleId><ArticleId IdType="pubmed">35663296</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M. Precision Nomothetic Medicine in Depression Research: A New Depression Model, and New Endophenotype Classes and Pathway Phenotypes, and A Digital Self. J. Pers. Med. 2022;12:403. doi: 10.3390/jpm12030403.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12030403</ArticleId><ArticleId IdType="pmc">PMC8955533</ArticleId><ArticleId IdType="pubmed">35330403</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Kubera M., Kota&#x144;ska M. Aberrations in the Cross-Talks Among Redox, Nuclear Factor-&#x3ba;B, and Wnt/&#x3b2;-Catenin Pathway Signaling Underpin Myalgic Encephalomyelitis and Chronic Fatigue Syndrome. Front. Psychiatry. 2022;13:822382. doi: 10.3389/fpsyt.2022.822382.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2022.822382</ArticleId><ArticleId IdType="pmc">PMC9120845</ArticleId><ArticleId IdType="pubmed">35599774</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu&#xf1;oz-Corona C., Guti&#xe9;rrez-Canales L.G., Ortiz-Ledesma C., Mart&#xed;nez-Navarro L.J., Mac&#xed;as A.E., Scavo-Montes D.A., Guan&#xed;-Guerra E. Quality of life and persistence of COVID-19 symptoms 90 days after hospital discharge. J. Int. Med. Res. 2022;50:3000605221110492. doi: 10.1177/03000605221110492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/03000605221110492</ArticleId><ArticleId IdType="pmc">PMC9284218</ArticleId><ArticleId IdType="pubmed">35822272</ArticleId></ArticleIdList></Reference><Reference><Citation>Case K.R., Wang C.P., Hosek M.G., Lill S.F., Howell A.B., Taylor B.S., Bridges J., MacCarthy D.J., Winkler P., Tsevat J. Health-related quality of life and social determinants of health following COVID-19 infection in a predominantly Latino population. J. Patient Rep. Outcomes. 2022;6:72. doi: 10.1186/s41687-022-00473-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41687-022-00473-8</ArticleId><ArticleId IdType="pmc">PMC9219362</ArticleId><ArticleId IdType="pubmed">35737279</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P., Patel K., Pinto C., Jaiswal R., Tirupathi R., Pillai S., Patel U. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-A systematic review and meta-analysis. J. Med. Virol. 2022;94:253&#x2013;262. doi: 10.1002/jmv.27309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27309</ArticleId><ArticleId IdType="pmc">PMC8662132</ArticleId><ArticleId IdType="pubmed">34463956</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M., Manoharan L., Elkheir N., Cheng V., Dagens A., Hastie C., O&#x2019;Hara M., Suett J., Dahmash D., Bugaeva P., et al. Characterising long COVID: A living systematic review. BMJ Glob. Health. 2021;6:e005427. doi: 10.1136/bmjgh-2021-005427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandasena H.M.R.K.G., Pathirathna M.L., Atapattu A.M.M.P., Prasanga P.T.S. Quality of life of COVID 19 patients after discharge: Systematic review. PLoS ONE. 2022;17:e0263941. doi: 10.1371/journal.pone.0263941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0263941</ArticleId><ArticleId IdType="pmc">PMC8849513</ArticleId><ArticleId IdType="pubmed">35171956</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Vojdani A., Galecki P., Kanchanatawan B. How to Construct a Bottom-Up Nomothetic Network Model and Disclose Novel Nosological Classes by Integrating Risk Resilience and Adverse Outcome Pathways with the Phenome of Schizophrenia. Brain Sci. 2020;10:645. doi: 10.3390/brainsci10090645.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci10090645</ArticleId><ArticleId IdType="pmc">PMC7565440</ArticleId><ArticleId IdType="pubmed">32957709</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Kanchanatawan B. In (deficit) schizophrenia, a general cognitive decline partly mediates the effects of neuro-immune and neuro-oxidative toxicity on the symptomatome and quality of life. CNS Spectr. 2021;12:1&#x2013;10. doi: 10.1017/S1092852921000419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1092852921000419</ArticleId><ArticleId IdType="pubmed">33843548</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Vojdani A., Sirivichayakul S., Barbosa D.S., Kanchanatawan B. Inflammatory and Oxidative Pathways Are New Drug Targets in Multiple Episode Schizophrenia and Leaky Gut, Klebsiella pneumoniae, and C1q Immune Complexes Are Additional Drug Targets in First Episode Schizophrenia. Mol. Neurobiol. 2021;58:3319&#x2013;3334. doi: 10.1007/s12035-021-02343-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02343-8</ArticleId><ArticleId IdType="pubmed">33675500</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton M. A rating scale for depression. J. Neurol. Neurosurg Psychiatry. 1960;23:56&#x2013;62. doi: 10.1136/jnnp.23.1.56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.23.1.56</ArticleId><ArticleId IdType="pmc">PMC495331</ArticleId><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . WHOQOL: Measuring Quality of Life. The World Health Organization; Geneva, Switzerland: 1997.</Citation></Reference><Reference><Citation>Beck A.T., Steer R.A., Brown G. Beck Depression Inventory&#x2013;II (BDI-II) [Database Record] APA PsycTests. 1996 doi: 10.1037/t00742-000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/t00742-000</ArticleId></ArticleIdList></Reference><Reference><Citation>Zachrisson O., Regland B., Jahreskog M., Kron M., Gottfries C.G. A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale) J. Psychosom. Res. 2002;52:501&#x2013;509. doi: 10.1016/S0022-3999(01)00315-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3999(01)00315-4</ArticleId><ArticleId IdType="pubmed">12069875</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 1959;32:50&#x2013;55. doi: 10.1111/j.2044-8341.1959.tb00467.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2044-8341.1959.tb00467.x</ArticleId><ArticleId IdType="pubmed">13638508</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes C.S., Maes M., Roomruangwong C., Moraes J.B., Bonifacio K.L., Vargas H.O., Barbosa D.S., Anderson G., de Melo L.G.P., Drozdstoj S., et al. Lowered quality of life in mood disorders is associated with increased neuro-oxidative stress and basal thyroid-stimulating hormone levels and use of anticonvulsant mood stabilizers. J. Eval. Clin. Pract. 2018;24:869&#x2013;878. doi: 10.1111/jep.12918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jep.12918</ArticleId><ArticleId IdType="pubmed">29665163</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavicchioli F.L., Maes M., Roomruangwong C., Bonifacio K.L., Barbosa D.S., Anderson G., Vargas H.O., Nunes S.O.V. Associations between severity of anxiety and clinical and biological features of major affective disorders. Psychiatry Res. 2018;260:17&#x2013;23. doi: 10.1016/j.psychres.2017.11.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2017.11.024</ArticleId><ArticleId IdType="pubmed">29156296</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanchanatawan B., Sriswasdi S., Maes M. Supervised machine learning to decipher the complex associations between neuro-immune biomarkers and quality of life in schizophrenia. Metab. Brain Dis. 2019;34:267&#x2013;282. doi: 10.1007/s11011-018-0339-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-018-0339-7</ArticleId><ArticleId IdType="pubmed">30467771</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Musawi A.F., Al-Hakeim H.K., Al-Khfaji Z.A., Al-Haboby I.H., Almulla A.F., Maes M. In schizophrenia, the effects of the IL-6/IL-23/Th17 axis on health-related quality of life and disabilities are partly mediated by generalized cognitive decline and the symptomatome. medRxiv. 2022 doi: 10.1101/2022.04.30.22274531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.04.30.22274531</ArticleId><ArticleId IdType="pmc">PMC9690590</ArticleId><ArticleId IdType="pubmed">36429996</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirivichayakul S., Kanchanatawan B., Thika S., Carvalho A.F., Maes M. A New Schizophrenia Model: Immune Activation is Associated with the Induction of Different Neurotoxic Products which Together Determine Memory Impairments and Schizophrenia Symptom Dimensions. CNS Neurol. Disord. Drug Targets. 2019;18:124&#x2013;140. doi: 10.2174/1871527317666181119115532.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527317666181119115532</ArticleId><ArticleId IdType="pubmed">30451122</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Moraes J.B., Congio A., Bonifacio K.L., Barbosa D.S., Vargas H.O., Michelin A.P., Carvalho A.F., Nunes S.O.V. Development of a Novel Staging Model for Affective Disorders Using Partial Least Squares Bootstrapping: Effects of Lipid-Associated Antioxidant Defenses and Neuro-Oxidative Stress. Mol. Neurobiol. 2019;56:6626&#x2013;6644. doi: 10.1007/s12035-019-1552-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1552-z</ArticleId><ArticleId IdType="pubmed">30911933</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Moraes J.B., Bonifacio K.L., Barbosa D.S., Vargas H.O., Michelin A.P., Nunes S.O.V. Towards a new model and classification of mood disorders based on risk resilience, neuro-affective toxicity, staging, and phenome features using the nomothetic network psychiatry approach. Metab. Brain Dis. 2021;36:509&#x2013;521. doi: 10.1007/s11011-020-00656-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-020-00656-6</ArticleId><ArticleId IdType="pubmed">33411213</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Kubera M., Stoyanova K., Leunis J.C. The Reification of the Clinical Diagnosis of Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) as an Immune and Oxidative Stress Disorder: Construction of a Data-driven Nomothethic Network and Exposure of ME/CFS Subgroups. Curr. Top. Med. Chem. 2021;21:1488&#x2013;1499. doi: 10.2174/1568026621666210727170147.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026621666210727170147</ArticleId><ArticleId IdType="pubmed">34315375</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hakeim H.K., Al-Naqeeb T.H., Almulla A.F., Maes M. The physio-affective phenome of major depression is strongly associated with biomarkers of astroglial and neuronal projection toxicity which in turn are associated with peripheral inflammation, insulin resistance and lowered calcium. medRxiv. 2022 doi: 10.1101/2022.07.04.22277246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.07.04.22277246</ArticleId><ArticleId IdType="pubmed">36996718</ArticleId></ArticleIdList></Reference><Reference><Citation>Mousa R.F., Smesam H.N., Qazmooz H.A., Al-Hakeim H.K., Maes M. A pathway phenotype linking metabolic, immune, oxidative, and opioid pathways with comorbid depression, atherosclerosis, and unstable angina. CNS Spectr. 2021;27:1&#x2013;15. doi: 10.1017/S1092852921000432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1092852921000432</ArticleId><ArticleId IdType="pubmed">34039448</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hakeim H.K., Hadi H.H., Jawad G.A., Maes M. Intersections between Copper, &#x3b2;-Arrestin-1, Calcium, FBXW7, CD17, Insulin Resistance and Atherogenicity Mediate Depression and Anxiety Due to Type 2 Diabetes Mellitus: A Nomothetic Network Approach. J. Pers. Med. 2022;12:23. doi: 10.3390/jpm12010023.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12010023</ArticleId><ArticleId IdType="pmc">PMC8779500</ArticleId><ArticleId IdType="pubmed">35055338</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong J., Khan A. Hypocalcemia: Updates in diagnosis and management for primary care. Can. Fam. Physician. 2012;58:158&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3279267</ArticleId><ArticleId IdType="pubmed">22439169</ArticleId></ArticleIdList></Reference><Reference><Citation>Bove-Fenderson E., Mannstadt M. Hypocalcemic disorders. Best Pract. Res. Clin. Endocrinol. Metab. 2018;32:639&#x2013;656. doi: 10.1016/j.beem.2018.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2018.05.006</ArticleId><ArticleId IdType="pubmed">30449546</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J.L. Hypercalcemia (High Level of Calcium in the Blood)&#x2014;Hormonal and Metabolic Disorders&#x2014;MSD Manual Consumer Version. Content last modified October 2021.  [(accessed on 22 July 2022)].  Available online:  https://www.msdmanuals.com/</Citation></Reference><Reference><Citation>Alemzadeh E., Alemzadeh E., Ziaee M., Abedi A., Salehiniya H. The effect of low serum calcium level on the severity and mortality of COVID patients: A systematic review and meta-analysis. Immun. Inflamm. Dis. 2021;9:1219&#x2013;1228. doi: 10.1002/iid3.528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.528</ArticleId><ArticleId IdType="pmc">PMC8589360</ArticleId><ArticleId IdType="pubmed">34534417</ArticleId></ArticleIdList></Reference><Reference><Citation>Faro M., S&#xe0;ez-Franc&#xe1;s N., Castro-Marrero J., Aliste L., Fern&#xe1;ndez de Sevilla T., Alegre J. Gender differences in chronic fatigue syndrome. Reumatol. Clin. 2016;12:72&#x2013;77. doi: 10.1016/j.reuma.2015.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reuma.2015.05.007</ArticleId><ArticleId IdType="pubmed">26190206</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble R.E. Depression in women. Metabolism. 2005;54((Suppl. S1)):49&#x2013;52. doi: 10.1016/j.metabol.2005.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2005.01.014</ArticleId><ArticleId IdType="pubmed">15877314</ArticleId></ArticleIdList></Reference><Reference><Citation>Somers J.M., Goldner E.M., Waraich P., Hsu L. Prevalence and incidence studies of anxiety disorders: A systematic review of the literature. Can. J. Psychiatry. 2006;51:100&#x2013;113. doi: 10.1177/070674370605100206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/070674370605100206</ArticleId><ArticleId IdType="pubmed">16989109</ArticleId></ArticleIdList></Reference><Reference><Citation>Songtachalert T., Roomruangwong C., Carvalho A.F., Bourin M., Maes M. Anxiety Disorders: Sex Differences in Serotonin and Tryptophan Metabolism. Curr. Top. Med. Chem. 2018;18:1704&#x2013;1715. doi: 10.2174/1568026618666181115093136.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026618666181115093136</ArticleId><ArticleId IdType="pubmed">30430940</ArticleId></ArticleIdList></Reference><Reference><Citation>Almulla A.F., Supasitthumrong T., Tunvirachaisakul C., Algon A.A.A., Al-Hakeim H.K., Maes M. The tryptophan catabolite or kynurenine pathway in COVID-19 and critical COVID-19: A systematic review and meta-analysis. BMC Infect. Dis. 2022;22:615. doi: 10.1186/s12879-022-07582-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07582-1</ArticleId><ArticleId IdType="pmc">PMC9284970</ArticleId><ArticleId IdType="pubmed">35840908</ArticleId></ArticleIdList></Reference><Reference><Citation>Couzin-Frankel J., Vogel G. Vaccines may cause rare, Long COVID-like symptoms. Science. 2022;375:364&#x2013;366. doi: 10.1126/science.ada0536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.ada0536</ArticleId><ArticleId IdType="pubmed">35084966</ArticleId></ArticleIdList></Reference><Reference><Citation>Seneff S., Nigh G., Kyriakopoulos A.M., McCullough P.A. Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs. Food Chem. Toxicol. 2022;164:113008. doi: 10.1016/j.fct.2022.113008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2022.113008</ArticleId><ArticleId IdType="pmc">PMC9012513</ArticleId><ArticleId IdType="pubmed">35436552</ArticleId></ArticleIdList></Reference><Reference><Citation>Keskin I., Gunal M.Y., Ayturk N., Kilic U., Ozansoy M., Kilic E. Dose-dependent neuroprotective effect of enoxaparin on cold-induced traumatic brain injury. Neural Regen. Res. 2017;12:761&#x2013;764. doi: 10.4103/1673-5374.206646.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.206646</ArticleId><ArticleId IdType="pmc">PMC5461613</ArticleId><ArticleId IdType="pubmed">28616032</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardillo G., Viggiano G.V., Russo V., Mangiacapra S., Cavalli A., Castaldo G., Agrusta F., Bellizzi A., Amitrano M., Iannuzzo M., et al. Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The Fondenoxavid Study. J. Blood. Med. 2021;12:69&#x2013;75. doi: 10.2147/JBM.S285214.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JBM.S285214</ArticleId><ArticleId IdType="pmc">PMC7886238</ArticleId><ArticleId IdType="pubmed">33603528</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann J.M., Mary V., Wahl F., Grosjean-Piot O., Uzan A., Pratt J. Neuroprotective profile of enoxaparin, a low molecular weight heparin, in in vivo models of cerebral ischemia or traumatic brain injury in rats: A review. CNS Drug Rev. 2002;8:1&#x2013;30. doi: 10.1111/j.1527-3458.2002.tb00213.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1527-3458.2002.tb00213.x</ArticleId><ArticleId IdType="pmc">PMC6741656</ArticleId><ArticleId IdType="pubmed">12070524</ArticleId></ArticleIdList></Reference><Reference><Citation>Shastri M.D., Stewart N., Horne J., Zaidi S.T., Sohal S.S., Peterson G.M., Korner H., Gueven N., Patel R.P. Non-Anticoagulant Fractions of Enoxaparin Suppress Inflammatory Cytokine Release from Peripheral Blood Mononuclear Cells of Allergic Asthmatic Individuals. PLoS ONE. 2015;10:e0128803. doi: 10.1371/journal.pone.0128803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0128803</ArticleId><ArticleId IdType="pmc">PMC4457428</ArticleId><ArticleId IdType="pubmed">26046354</ArticleId></ArticleIdList></Reference><Reference><Citation>Dos Reis Louzano A.S., de Moura E., Dias M., Lopes da Concei&#xe7;&#xe3;o L., Ant&#xf4;nio de Oliveira Mendes T., Gouveia Peluzio M.D.C. Ceftriaxone causes dysbiosis and changes intestinal structure in adjuvant obesity treatment. Pharmacol. Rep. 2022;74:111&#x2013;123. doi: 10.1007/s43440-021-00336-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-021-00336-x</ArticleId><ArticleId IdType="pubmed">34757518</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Scharp&#xe9; S., De Meester I., Goossens P., Wauters A., Neels H., Verkerk R., De Meyer F., D&#x2019;Hondt P., Peeters D., et al. Components of biological variation in prolyl endopeptidase and dipeptidyl-peptidase IV activity in plasma of healthy subjects. Clin. Chem. 1994;40:1686&#x2013;1691. doi: 10.1093/clinchem/40.9.1686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinchem/40.9.1686</ArticleId><ArticleId IdType="pubmed">7915215</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>